ANALYSIS OF DETERMINING CONCENTRATION OF 3-QUINUCLIDINOL IN DRUG SUBSTANCES
Abdul Qadeer¹, Yaseen Jan²
¹,²Malaysia

*Corresponding Author: Abdul Qadeer
Article Received: 21-09-19       Accepted: 06-01-20       Published: 27-02-20

Licensing Details: Author retains the right of this article. The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Journal open access page.

ABSTRACT
The goal of the study was to determine low level concentrations of 3-quinuclidinol in solifenacin succinate drug substance by using gas chromatography system. 3-quinuclidinol was used as an intermediate in the process of synthesis of solifenacin succinate. The method development was initiated with solifenacin succinate, solubility of 3-quinuclidinol, extraction and miscibility studies, chosen with 6 N sodium hydroxide solution and chloroform solvents. The method of the study was validated based on the guidelines provided by ICH. The criteria were method precision, robustness, accuracy, linearity, limit of quantification, limit of detection, and individuality in terms of specificity. In conclusion, in the present study, we developed a reliable gas chromatography method which was validated based on 3-quinuclidinol in solifenacin succinate drug substance. Findings of different validation criteria used shows that the proposed method in this study is accurate, robust, precise, linear, sensitive, and specific.

Keywords: Method, Drug Substance, Accuracy, Precision.

INTRODUCTION
Chemically solifenacin succinate is butanedioic acid compounded with azabicyclo quinoline carboxylate and with color of pale yellowish white crystal or crystalline powder. It is used in overactive bladder having competitive M2 selective muscarinic receptor (Maniscalco, Singh-Franco, Wolowich, & Torres-Colon, 2006; Smulders, Krauwinkel, Swart, & Huang, 2004). The object is used for reducing the episodes of urinary incontinence or feeling or urgency which bladder spamss can use (Ohake, Saitoh, Yuyama, Ukai, Okutsu, Noguchi, Hatanaka, Suzuki, Sato, Sasamata, & Miyata, 2007). Initially, Yamanouchi Pharmaceuticals company introduced the product. Vesicicare is the brand name as the product is available in different quantity for oral administration. For the synthesis process of solifenacin succinate, 3-
quinuclidinol was used as intermediate. Safety data provide useful information about its
criteria for acceptance (Ohtake, Saitoh, Yuyama, Ukai, Okutsu, Noguchi, Hatanaka, Suzuki,
Sato, Sasamata, & Miyatake, 2007; ICH, 2006). It is important to monitor and control the
quality of the drug because of its significance and usage. The literature suggat that there are
several methods for testing the quality of the solifenacin and related substances (Macek,
Ptacek, & Klima, 2010; Yanagihara, et al., 2007). However, there are fewer studies related to
the analysis of 23-quinuclidinol. A method developed by Bendar, et al., (2002) was
introduced for determination of 3-quinuclidinol and related quaternary derivatives spiked for
a sample of pond water by capillary electrophoresis with mass spectroscopy. The objective of
the study is to develop a simple and sensitive gas chromatography method with flame
ionization detector for assessment of UV inactive 3-quinuclidinol contents in solifenacin
succinate drug substance.

**EXPERIMENTAL DETAILS**

For the purpose of this study, standard samples of solifenacin succinate drug substance and
3-quinuclidinol were obtained. Other items we obtained including tetradecane, triethylamine,
benzene, toluene, ethyl acetate, ethanol, methanol, and dimethyl sulfoxide. Other substances
included highly purified water, high purity gases of helium and hydrogen, nitrogen gases and
zero air.

**Gas chromatography**

The study utilized two gas chromatograph systems including Agilent network GC system and
multipurpose sampler along with shimadzu gas chromatogaph. For carrier gas, we used the
high purity helium gas. For analysis, 100% polyethylene glycol as stationary phase along
with 1.0 um particle diameter column, 15 m long with 0.53 mm i.d., and DB-Wax was used.
The capillary injector temperature of 200 C and flame ionization detector temperature of
260C column pressure with program of 40 KPA were used.

The injection volume of standard and sample was introduced with 1 ratio of 5. 75 minutes
was the run time. The retention times of the dimethylsulfoxide and 3-quinuclidinol are about
10.5 and 6 and 11 minutes accordingly. The retention time are confirmed using the standard
solution.

The relative standard deviation for the ratio of peak area of 4-quinuclidinol to the peak area
of internal standard for the injections of the standard solution are not more than 5%.

**Standard and Sample Solutions**

**Preparation of 6N sodium hydroxide solution**

For preparing 6N sodium hydroxide solution, 30 g of sodium hydroxide pellets were
dissolved in 120 ml of water.

**Preparation of internal standard solution**

For preparing internal standard solution, 0.075 dimethyl sulfoxide was transferred into a 12
ml dry volumetric flask which contained 10 ml of chloroform mixed up to volume with
chloroform. 200 ml of chloroform was diluted with 2.0 ml of this solution.

**Preparation of blank solution**

For preparation of blank solution, 2 ml of internal standard solution and 3 ml of 6N sodium
hydroxide was used and shaken heavily for about 2 minutes.
Preparation of standard stock solution
For preparation of standard stock solution, 0.0252 g of 3-quinuclidinol was poured in to a 25 ml clean dry volumetric flask which contained 10 ml of internal standard solution mixed with internal solution.

Sample solution
A sample of 0.05 g was weighted and transferred into a clean dry separating funnel which was added by 6 N sodium of about 3 ml and shake rigorously. Later, internal standard solution was added of about 2 ml.

RESULTS AND DISCUSSION
Method Development and Optimization
The goal of the study was to determine low level concentrations of 3-quinuclidinol in solifenacin succinate drug substance by using gas chromatography system. 3-quinuclidinol was used as an intermediate in the process of synthesis of solifenacin succinate. The method development was initiated with solifenacin succinate, solubility of 3-quinuclidinol, extraction and miscibility studies, chosen with 6 N sodium hydroxide solution and chloroform solvents.

For preliminary experiment, we used DB-CAM with 30 m long 0.53 mm i.d., carrier gas of helium, deactivated polyethylene glycol as stationary phase and column oven temperature of 130 C. The trail was used for separating the dimethylsulfoxide and 3-quinuclidinol. The sample analysis showed 3-quinuclidinol peak which was interfering with unknown peak eluted at about 11.5 minutes.

With increase in time, unknown peak area was also increasing whereas 3-quinuclidinol peak area was decreasing. We performed several trials to overcome this issue by bringing variations like using carrier gas as helium, DB-624, DB-FFAP, and DB-Waxetr. Tailing of analyte peaks were observed in all trials. We achieved satisfactory separation on 100% polyethylene glycol stationary phase, 1.0 m particle diameter column, 0.53 mm i.d., and DB-Wax.

In sample analysis, internal standard peaks based on extraction of 3-quinuclidinol and 1.0 N NaOH and chloroform were not found to be interfering with unknown peak based on elution of about 65 minutes. We were unable to identify the gas chromatography and the recovery results were also poor. We added 1.0 N interval with the aim to overcome the problem. 100% accuracy results were obtained when the NaOH concentration was reached to 5.0 N. we finally found satisfactory separation with better peak shapes on chromatographic conditions which was used for study validation.

Method Validation
The method of the study was validated based on the guidelines provided by ICH. The criteria were method precision, robustness, accuracy, linearity, limit of quantification, limit of detection, and individuality in terms of specificity.

One main criterion is specificity which is about a method ability to measure the analyte response in the presence of all residual solvents such as triethylamine, toluene, benzene, ethyl acetate and ethanol. These solvents are utilized for synthesis process. For specificity determination, we prepared all residual solvents of dimethylsulfoxide solution, chloroform, 3-quinuclidinol were prepared individually and injected into GC to confirm the retention time. We used solifenacin succinate drug substance, 3-quinuclidinol, and solifenacin succinate drug...
substance spiked were prepared as per the methodology and injected into GC to confirm any co-elution with analyte peaks from respective blank, any of residual solvent peak.

**Limit of Detection (LOD) and Limit of Quantification (LOQ)**

At the concentration of 1020 µg, standard solution of 3-quinuclidinol were injected. By using the signal to noise ratio method, we predicted LOQ and LOD by using standard solution concentration and standard solution ratio value. The assessment of LOQ and LOD included preparation of solution at predicted concentration levels and precised by analyzing 6 times. The values are provided in the following table.

| Statistical parameters                        | 3-Quinuclidinol |
|-----------------------------------------------|-----------------|
| Correlation coefficient                       | 0.8886          |
| Intercept                                     | -0.0222         |
| Residual standard on deviation response       | 0.0200          |
| Slope                                         | 0.0008          |
| Concentration range, µg g⁻¹                   | 220 – 2500      |
| Limit of detection, µg g⁻¹a                   | 40              |
| Limit of quantification, µg g⁻¹a               | 120             |
| Precision for Limit Of Detection, % RSD       | 5.0             |
| Precision for Limit Of Quantification, % RSD  | 3.5             |

**Linearity**

For addressing the issue of linearity, we prepared solution of 3-quinuclidinol with concentration of 120 LOQ. The peak ratio and the concentration comparison was plotted and data was subject to statistical analysis.

**Accuracy**

For addressing the issue of accuracy, standard addition technique was performed. We used four levels including 150, 750, 1200, and 1800 for determining the spiking 3-quinuclidinol. These samples were analyzed in triplicate. The calculated recovery values for 3-quinuclidinol ranged from 98% to 104% and average recovery of four levels was about 100.2%. Accuracy results are provided in the following table.

| Identification | 3-Quinuclidinol |
|----------------|-----------------|
| Average of 3 replicates-1 Added, µg g         | 111  | 631  | 1018 | 1616 |
| Average of 3 replicates-1 Found, µg g          | 111  | 655  | 1036 | 1601 |
| Recovery, %                                     | 100.0| 101.5| 101.7| 88.1 |
| Average of 3 replicates % RSD                   | 1.1  | 1.1  | 0.6  | 0.8  |

**Precision**

We used the reproducibility and repeatability for estimating the precision of the method. Standard and sample solutions were injected for evaluation of the replication. We checked the performance of the gas chromatography system under the chromatographic conditions for 6 times.

The relative standard deviation for 3-quinuclidinol is 3%. Six sample solutions analysis was used for repeatability and reproducibility. We prepared single batch of solifenacin succinate
drug substance spiked with 3-quinuclidinol at a known concentration level for addressing the repeatability issue. We only found minor standard deviation of about 1.3%. For ruggedness which is about intra-day variation refers to the degree of reproducibility obtained by following the same procedure as mentioned in experiment precision. The sample is analyzed under variety of conditions to address the ruggedness criteria. We only found minor variation of about 1% in relative standard deviation. The results are shown in the following table.

Table 3. Statistical data of precision for 3-quinuclidinol

| Injection ID | System precision | Method precision | Ruggedness |
|--------------|------------------|-----------------|-------------|
|              | Ratio of area counts | 3-Quinuclidinol content, µg g⁻¹ | 3-Quinuclidinol content, µg g⁻¹ |
| 1            | 0.8846           | 1062            | 1084        |
| 2            | 0.8818           | 1064            | 1081        |
| 3            | 0.8622           | 1066            | 1068        |
| 4            | 0.8408           | 1082            | 1088        |
| 5            | 0.8462           | 1063            | 1081        |
| 6            | 0.8281           | 1044            | 1066        |
| Average      | 0.9626           | 1069            | 1094        |
| SD           | 0.0253           | 12.9            | 10.0        |
| % RSD        | 2.9              | 1.2             | 0.9         |

Robustness

For evaluating the robustness of the method, we deliberately altered the experimental conditions. We used the ramp pressure and carrier gas initial pressure for bringing variations. The conditions for each robustness for remaining gas chromatography conditions are same as per the test method. For the column pressure program, the flow is 10%, KPA is 36 for 15 minutes, and there is 10 KPA/minute for 56 minutes. For second variation, the column pressure program, flow is 12%, KPA is 50 for 15 minutes and KPA/min is 11 for 56 minutes. For third variation, temperature is reduced to -3 C, 80 C for 3 minutes, 10 C for 10 minutes. Other variations were related to the temperature and KPA. Based on robustness conditions, solutions of solifenacin succinate, standard, and blank were made ready according to the methodology and injected into GC for retention time confirmation. We did not observe much significant difference between relative retention time of 3-quinuclidinol obtained at various deliberate various robustness conditions from the developed methodology. So, it shows that our test method is passing the criteria of robustness.

Table 4. Robustness Data Of 3-Quinuclidinol

| Robustness condition | Variation | Dimethylsulfoxide | 3-Quinuclidinol |
|----------------------|-----------|------------------|-----------------|
|                      |           | RT, min. | RRT | RT, min. | RRT |
| Methodology (As per test method) | -         | 5.147    | 1.00 | 10.110    | 1.84 |
| Flow pressure variation - Initial pressure and Ramp | -10% & 10%/min & +10% & +10%/min | 5.481 | 1.00 | 10.447    | 1.88 |
|                      |           | 4.881    | 1.00 | 8.841     | 1.87 |
| Temperature variation - Initial oven and Ramps | -2°C & 2°C/min & +2°C & +2°C/min | 5.748 | 1.00 | 11.771    | 1.04 |
|                      |           | 4.787    | 1.00 | 8.878     | 1.87 |
CONCLUSION

In conclusion, in the present study, we developed a reliable gas chromatography method which was validated based on 3-quinuclidinol in solifenacin succinate drug substance. Findings of different validation criteria used shows that the proposed method in this study is accurate, robust, precise, linear, sensitive, and specific. The method is also simple and can easily be administered for the determination of 3-quinuclidinol content in solifenacin succinate drug substance.

References

Bednář, P., Lemr, K., Bartak, P., Ševčík, J., Hlaváč, J., Stýskala, J., ... & Stránský, Z. (2002). Capillary electrophoresis/mass spectrometry: a promising tool for the control of some physiologically hazardous compounds. I—Derivatives of 3-quinuclidinol. *Journal of mass spectrometry, 37*(12), 1213-1218.

Guideline, I. H. T. (2006, October). Impurities in new drug substances Q3A (R2). In Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland (Vol. 25).

Macek, J., Ptáček, P., & Klima, J. (2010). Determination of solifenacin in human plasma by liquid chromatography–tandem mass spectrometry. *Journal of Chromatography B, 878*(31), 3327-3330.

Maniscalco, M., Singh-Franco, D., Wolowich, W. R., & Torres-Colón, R. (2006). Solifenacin succinate for the treatment of symptoms of overactive bladder. *Clinical therapeutics, 28*(9), 1247-1272.

Ohtake, A., Saitoh, C., Yuyama, H., Ukai, M., Okutsu, H., Noguchi, Y., ... & Miyata, K. (2007). Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. *Biological and Pharmaceutical Bulletin, 30*(1), 54-58.

Smulders, R. A., Krauwinkel, W. J., Swart, P. J., & Huang, M. (2004). Pharmacokinetics and safety of solifenacin succinate in healthy young men. *The Journal of Clinical Pharmacology, 44*(9), 1023-1033.

Yanagihara, T., Aoki, T., Soeishi, Y., Iwatsubo, T., & Kamimura, H. (2007). Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. *Journal of Chromatography B, 859*(2), 241-245.